SEHK:9966
SEHK:9966Biotechs

A Look At Alphamab Oncology (SEHK:9966) Valuation After KN035 Regulatory Milestone In Biliary Tract Cancer

The latest development at Alphamab Oncology (SEHK:9966) involves China’s regulator formally accepting its new drug application for KN035, in combination with Gemcitabine and Oxaliplatin, for first-line treatment of unresectable or metastatic biliary tract cancer. See our latest analysis for Alphamab Oncology. After the NMPA accepted the KN035 filing, Alphamab Oncology’s HK$10.28 share price sits alongside a 1-year total shareholder return of 216.31%, while the 90-day share price return of a...